Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention

International Journal of Drug Policy

Volumn 17, Issue 3, 2006, Pages 211-221

  Hutchinson, Sharon J ^a,b   Bird, Sheila M ^b,c   Taylor, Avril ^d   Goldberg, David J ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

Harm reduction; Hepatitis C; Injecting drug use; Modelling; Prevention

Indexed keywords

ARTICLE; DRUG ABUSE; DRUG WITHDRAWAL; GLASGOW OUTCOME SCALE; HARM REDUCTION; HEPATITIS C; HEPATITIS C VIRUS; INCIDENCE; INFECTION PREVENTION; INFECTION SENSITIVITY; INTRAVENOUS DRUG ABUSE; NEEDLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROPREVALENCE; SIMULATION; STOCHASTIC MODEL; SYRINGE; VIRUS TRANSMISSION;

EID: 33744804252     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2006.02.008     Document Type: Article

References (49)

1. Alter H.J., and Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Seminers on Liver Disease 20 (2000) 17-35
2. Atkinson J. A simulation model of the dynamics of HIV transmission in intravenous drug users. Computers and Biomedical Research 29 (1996) 338-349
3. Bath G.E., Burns S.M., Davies A.G., Dominy N., Peters A., and Richardson A. Fewer drug users share needles. British Medical Journal 306 (1993) 1414
4. Bird S.M., Goldberg D.J., and Hutchinson S.J. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Journal of Epidemiology and Biostatistics 6 (2001) 243-265
5. CDC. Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. Morbidity and Mortality Weekly Report 46 (1997) 603-606
6. Crofts N., Aitken C.K., and Kaldor J.M. The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not. Medical Journal of Australia 170 (1999) 220-221
7. Crofts N., Caruana S., Bowden S., and Kerger M. Minimising harm from hepatitis C virus needs better strategies. British Medical Journal 321 (2000) 899
8. Ditton J., and Speirits K. The rapid increase of heroin-addiction in Glasgow during 1981 (1982), Department of Sociology, University of Glasgow, Glasgow
9. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 5079 (1992, October 2) 135-140
10. Frischer M., Bloor M., Green S., Goldberg D., McKeganey N., Covell R., et al. Reduction in needle sharing among community wide sample of injecting drug users. International Journal of STD and AIDS 3 (1992) 288-290
11. Frischer M., Goldberg D., Rahman M., and Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 92 (1997) 419-427
12. Friedland G.H., and Klein R.S. Transmission of the human immunodeficiency virus. New England Journal of Medicine 317 (1987) 1125-1135
13. Frischer M., Leyland A., Cormack R., Goldberg D.J., Bloor M., Green S.T., et al. Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. American Journal of Epidemiology 138 (1993) 170-181
14. Gerberding J.L. Management of occupational exposures to blood-borne viruses. New England Journal of Medicine 332 (1995) 444-451
15. Goldberg D., Burns S., Taylor A., Cameron S., Hargreaves D., and Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scandinavian Journal of Infectious Diseases 33 (2001) 457-461
16. Goldstein M.F., Friedman S.R., Neaigus A., Jose B., Ildefonso G., and Curtis R. Self-reports of HIV risk behavior by injecting drug users: Are they reliable?. Addiction 90 (1995) 1097-1104
17. Gore, S. M., & Bird, A. G. (1995). Cross-sectional Willing Anonymous Salivary HIV (WASH) surveillance studies and self-completion risk factor questionnaire in establishments of the Scottish Prison Service. ANSWER (Aids News Supplement to the SCIEH Weekly Report), 39, 1-4.
18. Gore S.M., Brettle R.P., Burns S.M., and Lewis S.C. Pilot study to estimate survivors to 1995 of 1983-84 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983-84. The Journal of Infections 37 (1998) 159-165
19. Green, S. T., Willocks, L. J., & Leen, C. L. S. (1991). The appearance of HIV among Edinburgh and Glasgow injecting drug users: Why do the HIV dissemination patterns differ so much between the two cities? ANSWER (Communicable Diseases (Scotland) Unit AIDS Supplement), 9, 1-2.
20. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Substance Use Misuse 33 (1998) 1197-1212
21. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91 (2001) 42-46
22. Ho-Yen D.O., Love W.C., and Follett E.A.C. Hepatitis B in adolescence and middle-age. Scottish Medical Journal 32 (1987) 45-47
23. Hutchinson S.J., Bird S.M., Taylor A., and Goldberg D.J. Estimating the prevalence, incidence and cessation of injecting drug use in Glasgow 1960-2000: Combining expert opinion with capture-recapture prevalence data. International Journal of Drug Policy 17 (2006) 29-34
24. Hutchinson S.J., Gore S.M., Taylor A., Goldberg D.J., and Frischer M. Extent and contributing factors of drug expenditure by injectors in Glasgow: A multi-site citywide cross-sectional study. British Journal of Pharmacology 176 (2000) 166-172
25. Hutchinson S.J., McIntyre P.G., Molyneaux P., Cameron S., Burns S., Taylor A., et al. Prevalence of hepatitis C among injectors in Scotland 1989-2000: Declining trends among young injectors halt in the late 1990s. Epidemiology and Infection 128 (2002) 473-477
26. Hutchinson S.J., Taylor A., Goldberg D.J., and Gruer L. Factors associated with injecting risk behaviours among serial community-wide samples of injecting drug users in Glasgow 1990-94: Implications for control and prevention of blood-borne viruses. Addiction 95 (2000) 931-940
27. Hutchinson S.J., Taylor A., Gruer L., Barr C., Mills C., Elliott L., et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction 95 (2000) 1055-1068
28. Jauncey M., Gilmour S., Micallef J., van Beek I., White P., Rawlinson W., et al. Longitudinal study of newly acquired hepatitis C infection among injecting drug users. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease. Australia, Sydney (2003)
29. Kretzschmar M., and Wiessing L.G. Modelling the spread of HIV in social networks of injecting drug users. AIDS 12 (1998) 801-811
30. Law M.G. Modelling the hepatitis C virus epidemic in Australia. Journal of Gastroenterology and Hepatology 14 (1999) 1100-1107
31. Longini, I. M., Jr., Clark, W. S., Haber, M., & Horsburgh, R., Jr. (1989). The stages of HIV infection: Waiting times and infection transmission probabilities. In Mathematical and statistical approaches to AIDS epidemiology (Lecture Notes in Biomathematics), (Vol. 83, pp. 111-137). Berlin: Springer Verlag.
32. MacDonald M., Law M., Hales J., Kaldor J.M., and Dore G.J. Impact of needle and syringe programs on HCV transmission among injecting drug users: A systematic review. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease. Sydney (2003) 143 (abstract)
33. Marcellin P. Hepatitis C: The clinical spectrum of the disease. Journal of Hepatology 31 (1999) 9-16
34. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 359 9316 (2002, April 27) 1478-1483
35. Menoyo C., Lamikiz E., Zulaika D., Urcelai A., Zubia I., and Martinez De Pancorbo M. The validation of statements by IDUs based on the analysis of blood traces on their used syringes. AIDS Care 10 4 (1998, August) 409-414
36. Murray J.M., Law M.G., Gao Z., and Kaldor J.M. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. International Journal of Epidemiology 32 (2003) 708-714
37. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. Journal of Hepatology 34 (2001) 730-739
38. Robertson J.R., Bucknall A.B.V., and Wiggins P. Regional variations in HIV antibody seropositivity in British intravenous drug users. Lancet 1 (1986) 1435-1436
39. Ross M.W., Stowe A., Wodak A., and Gold J. Reliability of interview responses of injecting drug users. Journal of Addictive Disease 14 (1995) 1-12
40. Roy K.M., Goldberg D., Taylor A., Hutchinson S., MacDonald L., Wilson K.S., et al. A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993-98. Journal of Infections 43 3 (2001, October) 200-205
41. Simmonds, P., Mutimer, D., & Follett, E. A. C. (1998). Hepatitis C. In W. Topley, Microbiology and microbial infections (9th ed., Vol. 1, Virology, pp. 726-727). London: Arnold.
42. Taylor A., Frischer M., Green S.T., Goldberg D., McKeganey N., and Gruer L. Low and stable prevalence of HIV among drug injectors in Glasgow. International Journal of STD & AIDS 5 (1994) 105-107
43. Taylor A., Goldberg D., Hutchinson S., Cameron S., and Fox R. High risk injecting behaviour among injectors from Glasgow: Cross sectional community-wide surveys 1990-1999. Journal of Epidemiology and Community Health 55 (2001) 766-767
44. Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S.M., McMenamin J., et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: Are current harm reduction strategies working?. Journal of Infections 40 (2000) 176-183
45. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 155 7 (2002, April 1) 645-653
46. Vickerman P., and Watts C. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: Model predictions. International Journal on Drug Policy 13 (2002) 149-164
47. Wejstål R. Sexual transmission of hepatitis C virus. Journal of Hepatology 31 Suppl. 1 (1999) 92-95
48. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 90 (2000) 1562-1569
49. Zwahlen M., and Vlahov D. Commentary: Modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users. International Journal of Epidemiology 32 (2003) 715-716